Cytokine Storm Due to Intralesional Intelukin-2 Therapy for Cutaneous In-Transit Melanoma.

This article discusses the case of a 65-year-old woman with metastatic melanoma who received intralesional interleukin-2 (IL-2) injections for in-transit disease. Intralesional IL-2 is a localized treatment option for melanoma that typically has mild side effects. However, in this case, the patient experienced a cytokine storm, a potentially life-threatening complication characterized by systemic cytokine release. The patient was hospitalized and received intensive care management. This case highlights the importance of early recognition and management of cytokine storms associated with intralesional IL-2 therapy. [Extracted from the article]